Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × BCG Vaccine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Recurrence 1 Non-Muscle Invasive Bladder Neoplasms 1

Interventions

venetoclax 19 Cyclophosphamide 17 pembrolizumab 15 Dexamethasone 14 Cytarabine 12 fludarabine 11 Azacitidine 10 Gemcitabine 9 pomalidomide 7 Rituximab 7 Carboplatin 7 selinexor 6 glofitamab 6 Temozolomide 6 Lenalidomide 6 Granulocyte Colony-Stimulating Factor 6 fludarabine phosphate 5 Paclitaxel 5 Oxaliplatin 5 Injections 5 Cisplatin 5 zanubrutinib 4 ruxolitinib 4 obinutuzumab 4 daratumumab 4 carfilzomib 4 Surgical Procedures, Operative 4 Nivolumab 4 Decitabine 4 Cladribine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05037279 2025-02-20

EVER

Verity Pharmaceuticals Inc.

Phase 3 Recruiting

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡